Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

[riky]

Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

<p><a href="http://news.yahoo.com/novartis-meningitis-b-vaccine-wins-breakthrough-therapy-status-054255977--finance.html"><img src="http://l3.yimg.com/bt/api/res/1.2/AjJGHRCMtt.xRy38VDfKlA--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-04-07T054255Z_1_CBREA360FWJ00_RTROPTP_2_NOVARTIS-RESULTS.JPG" width="130" height="86" alt="Logo of Swiss drugmaker Novartis is seen at its headquarters in Basel" align="left" title="Logo of Swiss drugmaker Novartis is seen at its headquarters in Basel" border="0" /></a>Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status. Bexsero is widely seen as crucial to Novartis' vaccines business, which has struggled to catch market leaders GlaxoSmithKline, Sanofi and Merck. The business was the only one of Novartis' five divisions to report a full-year operating loss in 2013. The vaccine already has approval in Europe, Canada and Australia and has been administered at several universities in the United States to stop outbreaks of meningitis across campuses.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login